Related Experiment Video
Updated: Jun 18, 2026

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Degradation and Detection: Integrating BCL6 Targeted Protein Degradation with Biomarker-Guided BET Inhibition in
Anna C Renner1, Robert B Kargbo2
1North Dakota State University, Fargo, North Dakota 58108-6050, United States.
None:
Targeted protein degradation and biomarker-guided therapy offer complementary strategies for controlling transcription-driven cancers. One approach eliminates BCL6 through heterobifunctional degraders, while another defines S100A8/A9-centered biomarkers that predict response to BET inhibition. Together, they reveal how combining protein elimination with molecular stratification can overcome resistance, refine patient selection, and enable more durable therapeutic responses in oncology.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

